How to Buy Amicus Therapeutics Stock
Amicus Therapeutics Inc
Amicus Therapeutics, Inc. , a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
Amicus Therapeutics stock last closed at $7.35, up 2.08% from the previous day, and has decreased 27.73% in one year. It has overperformed other stocks in the Biotechnology industry by 0.5 percentage points. Amicus Therapeutics stock is currently +18.55% from its 52-week low of $6.20, and -41.9% from its 52-week high of $12.65.
At the moment, there are 300.12M shares of FOLD outstanding. The market capitalization of FOLD is $2.21B. In the last 24 hours, 3.68M FOLD shares were traded.
How to Buy Amicus Therapeutics Stock
Not sure how to invest in Amicus Therapeutics stock? Here's how.
- Decide where to buy Amicus Therapeutics stock: You need to choose an online brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you determine where to buy Amicus Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit money your brokerage account: Choose your method of payment and add your info.
- Research Amicus Therapeutics stock: The Amicus Therapeutics ticker symbol is FOLD. Is Amicus Therapeutics stock a good investment? Should you buy shares of FOLD? How do FOLD's underlying business fundamentals look? Do top analysts think Amicus Therapeutics is a good buy? Why has FOLD's stock price moved recently? (Hint: Our stock research tools can help you figure out if FOLD is a good stock to buy).
- Execute your FOLD trade: Decide if you will purchase FOLD shares at the current market price or use a limit order to purchase FOLD shares at a particular price.
- Get the latest scoop on your FOLD position: Create a watchlist to track your position in Amicus Therapeutics shares.
Step 1: Decide where to buy Amicus Therapeutics stock
You will need a brokerage account to access the NASDAQ market and buy FOLD shares.
Our recommended brokerage: eToro
Based on our experience, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world financial markets: From Tech to Real Estate, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've selected the best brokerage, the next step is to fill out some personal info so you are able to invest in FOLD today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to open a new trading account.
- Send your information by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you have opened your account on the greatest app to buy stocks, you need to deposit funds:
Watch this video walkthrough if you need help transferring money into your brokerage account.
Step 4: Research Amicus Therapeutics stock
After you have figured out the best place to buy Amicus Therapeutics stock, it's critical to research their stock prior to investing, so you truly comprehend the risk and upside.
Amicus Therapeutics stock quick numbers
Amicus Therapeutics Overview
WallStreetZen was built to help everyday investors do better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on FOLD's stock page.
What is the fair value of FOLD stock?
Analysts use many financial metrics, analyses, models, and charts to gauge FOLD's fair value.
Using relative valuations measures:
- FOLD may be overvalued based on its P/B ratio of 11.37x, relative to Biotechnology industry P/B ratio of 4.26x
You can do additional valuation analysis on FOLD's stock here.
Is FOLD a healthy company?
Pros:
- FOLD has $249.95M in cash and short term investments. This is enough to cover its annual cash burn of $37.44M.
- There are more short-term assets than long-term liabilities on the FOLD balance sheet.
- FOLD has cash burn of 37444000. It has enough cash and short-term investments to cover this for at least one year.
- FOLD profit margin has gone up from -38% to -10.6% in the past year.
- There are more short-term assets than short-term liabilities on the FOLD balance sheet.
Cons:
- FOLD has a relatively high debt to equity ratio of 3.05.
- Total FOLD debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy Amicus Therapeutics stock, according to Wall Street analysts?
Out of 6 Equities analysts who give forecasts on FOLD, the consensus analyst rating on Amicus Therapeutics is a Strong Buy
Please note that analyst forecasts are not recommendations, nor are they financial advice.
Most Recent FOLD Analyst Upgrades/Downgrades
Karl Chalabala, a bottom 21% analyst from UBS maintains FOLD with a strong buy rating and raises their FOLD price target from $19.00 to $21.00, on Nov 7, 2024.
You can dig deeper into what analysts are forecasting on the Amicus Therapeutics stock forecast page.
FOLD Trading Indicators
FOLD Performance Numbers
Last year, FOLD revenue was $528.30M. In the past 5 year, FOLD's revenue has increased by 23.72% per year. This was slower than the Biotechnology industry average of 45.84%.
You can research FOLD's earnings and revenue performance here.
Who is buying/selling FOLD?
Over the last 12 months, executives and large shareholders at FOLD have sold more shares than they have bought.
Bradley L. Campbell, President and CEO of FOLD, was the latest FOLD insider to sell. They sold $119,037.50 worth of FOLD stock on Mar 15, 2025.
Learn more about who owns FOLD stock here.
Does FOLD provide a stable income stream?
No, Amicus Therapeutics doesn't provide an income stream by paying out dividends.
What do other investors have to say about FOLD?
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your FOLD trade
There are two primary types of orders:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are generally fine for most investors. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at an exact dollar amount limit, use a limit order.
Hit the Open Trade button and eToro will execute the order.
If you require more assistance investing in stocks on eToro, click the how to video below:
Step 6: Get the latest scoop on your FOLD position
Now that you own some FOLD stock, you'll want to keep up with your new investment.
Make a watchlist to track the most important metrics related to your FOLD stock.
FOLD Feed
How to Buy Stock in Amicus Therapeutics
To reiterate, here are the 6 steps for buying Amicus Therapeutics stock:
- Decide where to buy Amicus Therapeutics stock
- Open your brokerage account
- Deposit money your brokerage account
- Research Amicus Therapeutics stock
- Execute your FOLD trade
- Get the latest scoop on your FOLD position
If you require a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to monitor your investment in Amicus Therapeutics, add FOLD to your watchlist below.
Related "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.